Keeping close company: CCRM’s industry consortium

Whether you’re an industry member, an academic or an investor, networks and connections are a vital component of success in the field of regenerative medicine (RM) and CCRM is here to help. With a collective network of over 50 leading global RM companies, CCRM aids in fostering collaborations among emerging companies and individual researchers in the quest to develop novel and life-changing treatments.

CCRM was established in Canada in 2011, and since then has overseen tremendous success in the development of the Canadian RM and cell therapy industry. CCRM Australia has now been established and is modelled on the very successful CCRM. By becoming a member of the consortium, companies will be joining a group of over 50 of the world’s leading RM companies.

Opportunities to Members

Joining the CCRM industry consortium offers Australian RM companies unparalleled opportunities to access global RM networks. The current industry consortium includes large multinationals, small-medium enterprises (SME) and emerging biotechnology companies in important areas of RM, including pharmaceutical, devices, reagents, tools, biomaterials and cell therapies.

The benefits most valuable to individual RM companies include increased visibility to a global network of world-leading RM companies. It provides business skills, leadership, funds for product development and receptor capacity for technologies and products. Importantly, as funds from Australian companies that join the consortium will stay in Australia, it will help to support the local RM sector.

At CCRM Australia, we invite fellow Australian companies to join us and strengthen linkages within the global RM network.

For more information on the CCRM website, click here.

For more information, please contact: